https://m2.mtmt.hu/ hun 2026-09-21 06:35 JournalArticle 34094092 VALIDATED true Export Date: 11 October 2023 CODEN: VPAHA 0 false 2026-08-10T20:25:19.113+0000 2023-09-15T09:25:14.925+0000 2023-08-13T13:45:50.840+0000 true 10026589 Tichy Rita /api/admin/10026589 Admin Tichy Rita (SE_KK_Admin5_TR, admin) true 10026589 2026-06-16T08:15:42.833+0000 2023-08-28T11:34:06.542+0000 true 10080205 Szalóky-Siki Ágnes /api/admin/10080205 Admin Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Pálóczi, J. true true /api/journal/10001004 REVIEWED VASCULAR PHARMACOLOGY 1537-1891 1879-3649 true false 10001004 false 10001004 true 1537-1891 1879-3649 Journal FOREIGN 152 107208 107208 9 2023 Funding 2030208 /api/funding/2030208 (K139237) false true Funding 2030209 /api/funding/2030209 (RRF-2.3.1-21-2022-00003) false true Funding 2030210 /api/funding/2030210 (TKP2021-EGA-23) Támogató: Innovációs és Technológiai Minisztérium false true true 2023 true true true false true false NONE 2026-08-10 false 2 0 2 2 0 2 2 2 2 2 2 2 2 2 0 0 2 2 2 2 0 5 5 Folyóiratcikk Journal Article 24 2 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2025 0 2 2 2 2 Q1 false false false false 2023-08-27T11:34:06.275+0000 Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); MTA-SE Rendszerfarmakológiai Kutatócsoport (SE / AOK / I / FFI) 5 24 2 9 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 109577540 /api/authorship/109577540 Pálóczi, J. 1 0.11111111 true false false Pálóczi J. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109577541 /api/authorship/109577541 Paál, Á.* [Paál, Ágnes (farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 2 0.111 true false false Author 10077413 /api/author/10077413 Paál Ágnes (farmakológia) Paál Ágnes true true Paál Á. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109577542 /api/authorship/109577542 Pigler, J. 3 0.11111111 false false false Pigler J. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109577543 /api/authorship/109577543 Kiss, B. [Kiss, Bernadett (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); MTA-SE Rendszerfarmakológiai Kutatócsoport (SE / AOK / I / FFI) 4 0.111 false false false Author 10064374 /api/author/10064374 Kiss Bernadett (Farmakológia) Kiss Bernadett true 10064374 true Kiss B. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109577544 /api/authorship/109577544 Rhoden, A. 5 0.11111111 false false false Rhoden A. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109577545 /api/authorship/109577545 Varga, Z.V. [Varga, Zoltán (kardiovaszkuláris...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); MTA-SE Rendszerfarmakológiai Kutatócsoport (SE / AOK / I / FFI) 6 0.111 false false false Author 10028393 /api/author/10028393 Varga Zoltán (kardiovaszkuláris kutatás) Varga Zoltán true 10028393 true Varga Z.V. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109577546 /api/authorship/109577546 Ferdinandy, P. [Ferdinandy, Péter (Farmakológia, mol...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 7 0.111 false false false Author 10010125 /api/author/10010125 Ferdinandy Péter (Farmakológia, molekuláris medicina) Ferdinandy Péter true 10010125 true Ferdinandy P. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109577547 /api/authorship/109577547 Eschenhagen, T.** 8 0.111 false true false Eschenhagen T. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109577548 /api/authorship/109577548 Görbe, A. ✉ [Görbe, Anikó (orvostudomany), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); MTA-SE Rendszerfarmakológiai Kutatócsoport (SE / AOK / I / FFI) 9 0.111 false true true Author 10027602 /api/author/10027602 Görbe Anikó (orvostudomany) Görbe Anikó true 10027602 true Görbe A. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 24251252 /api/publicationidentifier/24251252 DOI: 10.1016/j.vph.2023.107208 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.1016/j.vph.2023.107208 https://doi.org/10.1016/j.vph.2023.107208 false true PublicationIdentifier 24375747 /api/publicationidentifier/24375747 WoS: 001058938800001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001058938800001 https://www.webofscience.com/wos/woscc/full-record/001058938800001 true true PublicationIdentifier 24310592 /api/publicationidentifier/24310592 Scopus: 85167969820 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85167969820 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85167969820 true true PublicationIdentifier 24251253 /api/publicationidentifier/24251253 PubMed: 37572973 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 37572973 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37572973&dopt=Abstract false true SjrRating 11406138 /api/sjrrating/11406138 sjr:Q1 (2023) Scopus - Pharmacology VASCULAR PHARMACOLOGY 1537-1891 1879-3649 77 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 3004 /api/classificationexternal/3004 Scopus - Pharmacology true 3004 true Q1 DIRECT true true Reference 44299555 /api/reference/44299555 1. Sun 2022: IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045., Diabetes Res. Clin. Pract., 183, DOI: 10.1016/j.diabres.2021.109119 1 10.1016/j.diabres.2021.109119 false true Reference 44299556 /api/reference/44299556 2. Morrish 2001: Mortality and causes of death in the WHO multinational study of vascular disease in diabetes., Diabetologia, 44, p. S14, DOI: 10.1007/PL00002934 2 10.1007/PL00002934 false true Reference 44299557 /api/reference/44299557 3. Einarson 2018: Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017., Cardiovasc. Diabetol., 17, p. 83, DOI: 10.1186/s12933-018-0728-6 3 10.1186/s12933-018-0728-6 false true Reference 44299558 /api/reference/44299558 4. Ford 2007: Explaining the decrease in U.S. deaths from coronary disease, 1980–2000., N. Engl. J. Med., 356, p. 2388, DOI: 10.1056/NEJMsa053935 4 10.1056/NEJMsa053935 false true Reference 44299559 /api/reference/44299559 5. Sidney 2016: Recent trends in cardiovascular mortality in the United States and public health goals., JAMA Cardiol., 1, p. 594, DOI: 10.1001/jamacardio.2016.1326 5 10.1001/jamacardio.2016.1326 false true Reference 44299560 /api/reference/44299560 6. Manemann 2021: Recent trends in cardiovascular disease deaths: a state specific perspective., BMC Public Health, 21, p. 1031, DOI: 10.1186/s12889-021-11072-5 6 10.1186/s12889-021-11072-5 false true Reference 44299561 /api/reference/44299561 7. Imes 2014: The obesity epidemic: the United States as a cautionary tale for the rest of the world., Curr. Epidemiol. Rep., 1, p. 82, DOI: 10.1007/s40471-014-0012-6 7 10.1007/s40471-014-0012-6 false true Reference 44299562 /api/reference/44299562 8. Beauloye 2001: No-flow ischemia inhibits insulin signaling in heart by decreasing intracellular pH., Circ. Res., 88, p. 513, DOI: 10.1161/01.RES.88.5.513 8 10.1161/01.RES.88.5.513 false true Reference 44299563 /api/reference/44299563 9. Dal Canto 2019: Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications., Eur. J. Prev. Cardiol., 26, p. 25, DOI: 10.1177/2047487319878371 9 10.1177/2047487319878371 false true Reference 44299564 /api/reference/44299564 10. Bertoluci 2017: Cardiovascular risk assessment in patients with diabetes., Diabetol. Metab. Syndr., 9, p. 25, DOI: 10.1186/s13098-017-0225-1 10 10.1186/s13098-017-0225-1 false true Reference 44299565 /api/reference/44299565 11. Hajar 2017: Risk factors for coronary artery disease: historical perspectives., Heart Views, 18, p. 109, DOI: 10.4103/HEARTVIEWS.HEARTVIEWS_106_17 11 10.4103/HEARTVIEWS.HEARTVIEWS_106_17 false true Reference 44299566 /api/reference/44299566 12. Fox 2004: The significant effect of diabetes duration on coronary heart disease mortality: the Framingham heart study., Diabetes Care, 27, p. 704, DOI: 10.2337/diacare.27.3.704 12 10.2337/diacare.27.3.704 false true Reference 44299567 /api/reference/44299567 13. Heather 2022: Guidelines on models of diabetic heart disease., Am. J. Physiol. Heart Circ. Physiol., 323, p. H176, DOI: 10.1152/ajpheart.00058.2022 13 10.1152/ajpheart.00058.2022 false true Reference 44299568 /api/reference/44299568 14. Purnama 2022: Modelling diabetic cardiomyopathy: using human stem cell-derived cardiomyocytes to complement animal models., Metabolites, 12, DOI: 10.3390/metabo12090832 14 10.3390/metabo12090832 false true Reference 44299569 /api/reference/44299569 15. Chen 2018: In vitro models of ischemia-reperfusion injury., Regen. Eng. Transl. Med., 4, p. 142, DOI: 10.1007/s40883-018-0056-0 15 10.1007/s40883-018-0056-0 false true Reference 44299570 /api/reference/44299570 16. Eschenhagen 1997: Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system., FASEB J., 11, p. 683, DOI: 10.1096/fasebj.11.8.9240969 16 10.1096/fasebj.11.8.9240969 false true Reference 44299571 /api/reference/44299571 17. Katare 2010: Engineered heart tissue: a novel tool to study the ischemic changes of the heart in vitro., PLoS One, 5, DOI: 10.1371/journal.pone.0009275 17 10.1371/journal.pone.0009275 false true Reference 44299572 /api/reference/44299572 18. Hansen 2010: Development of a drug screening platform based on engineered heart tissue., Circ. Res., 107, p. 35, DOI: 10.1161/CIRCRESAHA.109.211458 18 10.1161/CIRCRESAHA.109.211458 false true Reference 44299573 /api/reference/44299573 19. Funcke 2020: Effects of the Delta opioid receptor agonist DADLE in a novel hypoxia-Reoxygenation model on human and rat-engineered heart tissue: a pilot study., Biomolecules, 10, DOI: 10.3390/biom10091309 19 10.3390/biom10091309 false true Reference 44299574 /api/reference/44299574 20. Gorbe 2015: Protection by the NO-donor SNAP and BNP against hypoxia/Reoxygenation in rat engineered heart tissue., PLoS One, 10, DOI: 10.1371/journal.pone.0132186 20 10.1371/journal.pone.0132186 false true Reference 44299575 /api/reference/44299575 21. Song 2011: Engineered heart tissue model of diabetic myocardium., Tissue Eng. Part A, 17, p. 1869, DOI: 10.1089/ten.tea.2010.0617 21 10.1089/ten.tea.2010.0617 false true Reference 44299576 /api/reference/44299576 22. Wang 2021: Engineered cardiac tissues: a novel in vitro model to investigate the pathophysiology of mouse diabetic cardiomyopathy., Acta Pharmacol. Sin., 42, p. 932, DOI: 10.1038/s41401-020-00538-8 22 10.1038/s41401-020-00538-8 false true Reference 44299577 /api/reference/44299577 23. Zimmermann 2000: Three-dimensional engineered heart tissue from neonatal rat cardiac myocytes., Biotechnol. Bioeng., 68, p. 106, DOI: 10.1002/(SICI)1097-0290(20000405)68:1&lt;106::AID-BIT13&gt;3.0.CO;2-3 23 10.1002/(SICI)1097-0290(20000405)68:1&lt;106::AID-BIT13&gt;3.0.CO;2-3 false true Reference 44299578 /api/reference/44299578 24. Zimmermann 2006: Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts., Nat. Med., 12, p. 452, DOI: 10.1038/nm1394 24 10.1038/nm1394 false true Reference 44299579 /api/reference/44299579 25. Min 2009: The signal transduction pathway of PKC/NF-kappa B/c-fos may be involved in the influence of high glucose on the cardiomyocytes of neonatal rats., Cardiovasc. Diabetol., 8, p. 8, DOI: 10.1186/1475-2840-8-8 25 10.1186/1475-2840-8-8 false true Reference 44299580 /api/reference/44299580 26. Madonna 2020: Simulated hyperglycemia impairs insulin signaling in endothelial cells through a hyperosmolar mechanism., Vasc. Pharmacol., 130, DOI: 10.1016/j.vph.2020.106678 26 10.1016/j.vph.2020.106678 false true Reference 44299581 /api/reference/44299581 27. Li 2004: Role of connexin 43 in ischemic preconditioning does not involve intercellular communication through gap junctions., J. Mol. Cell. Cardiol., 36, p. 161, DOI: 10.1016/j.yjmcc.2003.10.019 27 10.1016/j.yjmcc.2003.10.019 false true Reference 44299582 /api/reference/44299582 28. Makkos 2019: A comorbidity model of myocardial ischemia/reperfusion injury and hypercholesterolemia in rat cardiac myocyte cultures., Front. Physiol., 10, p. 1564, DOI: 10.3389/fphys.2019.01564 28 10.3389/fphys.2019.01564 false true Reference 44299583 /api/reference/44299583 29. Paloczi 2016: Exogenous nitric oxide protects human embryonic stem cell-derived cardiomyocytes against ischemia/reperfusion injury., Oxidative Med. Cell. Longev., 2016, p. 4298945, DOI: 10.1155/2016/4298945 29 10.1155/2016/4298945 false true Reference 44299584 /api/reference/44299584 30. Vandenburgh 2008: Drug-screening platform based on the contractility of tissue-engineered muscle., Muscle Nerve, 37, p. 438, DOI: 10.1002/mus.20931 30 10.1002/mus.20931 false true Reference 44299585 /api/reference/44299585 31. Samidurai 2017: Chronic treatment with novel nanoformulated micelles of rapamycin, Rapatar, protects diabetic heart against ischaemia/reperfusion injury., Br. J. Pharmacol., 174, p. 4771, DOI: 10.1111/bph.14059 31 10.1111/bph.14059 false true Reference 44299586 /api/reference/44299586 32. Kristiansen 2019: Impact of hyperglycemia on myocardial ischemia-reperfusion susceptibility and ischemic preconditioning in hearts from rats with type 2 diabetes., Cardiovasc. Diabetol., 18, p. 66, DOI: 10.1186/s12933-019-0872-7 32 10.1186/s12933-019-0872-7 false true Reference 44299587 /api/reference/44299587 33. Penna 2020: Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols., Br. J. Pharmacol., 177, p. 5312, DOI: 10.1111/bph.14993 33 10.1111/bph.14993 false true Reference 44299588 /api/reference/44299588 34. Ferdinandy 2014: Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning., Pharmacol. Rev., 66, p. 1142, DOI: 10.1124/pr.113.008300 34 10.1124/pr.113.008300 false true Reference 44299589 /api/reference/44299589 35. Jennings 1960: Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog., Arch. Pathol., 70, p. 68 35 false true Reference 44299590 /api/reference/44299590 36. Gorbe 2010: Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation., Basic Res. Cardiol., 105, p. 643, DOI: 10.1007/s00395-010-0097-0 36 10.1007/s00395-010-0097-0 false true Reference 44299591 /api/reference/44299591 37. Luan 2009: High glucose sensitizes adult cardiomyocytes to ischaemia/reperfusion injury through nitrative thioredoxin inactivation., Cardiovasc. Res., 83, p. 294, DOI: 10.1093/cvr/cvp085 37 10.1093/cvr/cvp085 false true Reference 44299592 /api/reference/44299592 38. Qiu 2017: NLRP3 Inflammasome activation-mediated Pyroptosis aggravates myocardial ischemia/reperfusion injury in diabetic rats., Oxidative Med. Cell. Longev., 2017, p. 9743280, DOI: 10.1155/2017/9743280 38 10.1155/2017/9743280 false true Reference 44299593 /api/reference/44299593 39. Xu 2004: Contradictory effects of short- and long-term hyperglycemias on ischemic injury of myocardium via intracellular signaling pathway., Exp. Mol. Pathol., 76, p. 57, DOI: 10.1016/j.yexmp.2003.08.003 39 10.1016/j.yexmp.2003.08.003 false true Reference 44299594 /api/reference/44299594 40. Chen 2016: JNK/PI3K/Akt signaling pathway is involved in myocardial ischemia/reperfusion injury in diabetic rats: effects of salvianolic acid a intervention., Am. J. Transl. Res., 8, p. 2534 40 false true Reference 44299595 /api/reference/44299595 41. Pang 2002: Hyperglycemia inhibits capacitative calcium entry and hypertrophy in neonatal cardiomyocytes., Diabetes, 51, p. 3461, DOI: 10.2337/diabetes.51.12.3461 41 10.2337/diabetes.51.12.3461 false true Reference 44299596 /api/reference/44299596 42. Mapanga 2014: Detrimental effects of acute hyperglycaemia on the rat heart., Acta Physiol (Oxford), 210, p. 546, DOI: 10.1111/apha.12184 42 10.1111/apha.12184 false true Reference 44299597 /api/reference/44299597 43. Zalesak 2016: Hyperosmotic environment blunts effectivity of ischemic preconditioning against ischemia-reperfusion injury and improves ischemic tolerance in non-preconditioned isolated rat hearts., Physiol. Res., 65, p. 1045, DOI: 10.33549/physiolres.933362 43 10.33549/physiolres.933362 false true Reference 44299598 /api/reference/44299598 44. Ritchie 2020: Basic mechanisms of diabetic heart disease., Circ. Res., 126, p. 1501, DOI: 10.1161/CIRCRESAHA.120.315913 44 10.1161/CIRCRESAHA.120.315913 false true Reference 44299599 /api/reference/44299599 45. Hirt 2014: Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation., J. Mol. Cell. Cardiol., 74, p. 151, DOI: 10.1016/j.yjmcc.2014.05.009 45 10.1016/j.yjmcc.2014.05.009 false true Reference 44299600 /api/reference/44299600 46. Liu 2022: Metformin attenuates cardiac hypertrophy via the HIF-1alpha/PPAR-gamma signaling pathway in high-fat diet rats., Front. Pharmacol., 13 46 false true Reference 44299601 /api/reference/44299601 47. Liu 2023: Resveratrol inhibits autophagy against myocardial ischemia-reperfusion injury through the DJ-1/MEKK1/JNK pathway., Eur. J. Pharmacol., 951, DOI: 10.1016/j.ejphar.2023.175748 47 10.1016/j.ejphar.2023.175748 false true Reference 44299602 /api/reference/44299602 48. Volpe 2018: Cellular death, reactive oxygen species (ROS) and diabetic complications., Cell Death Dis., 9, p. 119, DOI: 10.1038/s41419-017-0135-z 48 10.1038/s41419-017-0135-z false true /api/publication/34094092 Pálóczi J. et al. Organ-specific model of simulated ischemia/reperfusion and hyperglycemia based on engineered heart tissue. (2023) VASCULAR PHARMACOLOGY 1537-1891 1879-3649 152<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" >Pálóczi J. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10077413"><a href="/gui2/?type=authors&mode=browse&sel=10077413" target="_blank">Paál Á.^* (<span class="authorship-author-name">Paál Ágnes</span> <span class="authorAux-mtmt"> farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Pigler J. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10064374"><a href="/gui2/?type=authors&mode=browse&sel=10064374" target="_blank">Kiss B. (<span class="authorship-author-name">Kiss Bernadett</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/MTA-SE Rendszerfarmakológiai Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Rhoden A. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10028393"><a href="/gui2/?type=authors&mode=browse&sel=10028393" target="_blank">Varga Z.V. (<span class="authorship-author-name">Varga Zoltán</span> <span class="authorAux-mtmt"> kardiovaszkuláris kutatás</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/MTA-SE Rendszerfarmakológiai Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10010125"><a href="/gui2/?type=authors&mode=browse&sel=10010125" target="_blank">Ferdinandy P. (<span class="authorship-author-name">Ferdinandy Péter</span> <span class="authorAux-mtmt"> Farmakológia, molekuláris medicina</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Eschenhagen T.^** </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10027602"><a href="/gui2/?type=authors&mode=browse&sel=10027602" target="_blank">Görbe A. ✉ (<span class="authorship-author-name">Görbe Anikó</span> <span class="authorAux-mtmt"> orvostudomany</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/MTA-SE Rendszerfarmakológiai Kutatócsoport</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;34094092" target="_blank">Organ-specific model of simulated ischemia/reperfusion and hyperglycemia based on engineered heart tissue</a></div> <div> <span class="journal-title">VASCULAR PHARMACOLOGY</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/1537-1891">1537-1891</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1879-3649">1879-3649</a>)</span>: <span class="journal-volume">152</span> <span class="page"> Paper 107208. 9 p. </span> <span class="year">(2023)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.1016/j.vph.2023.107208" target="_blank" href="https://doi.org/10.1016/j.vph.2023.107208"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001058938800001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001058938800001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85167969820" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85167969820"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="37572973" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37572973&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Pharmacology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Molecular Medicine&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Physiology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 2</span> | Független: 2 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 2 | Scopus jelölt:&nbsp;2 | WoS/Scopus jelölt:&nbsp;2 | DOI jelölt:&nbsp;2 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;34094092&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 5 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 34094092</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (K139237), (RRF-2.3.1-21-2022-00003), (TKP2021-EGA-23) Támogató: Innovációs és Technológiai Minisztérium </div> <div class="lastModified">Utolsó módosítás: 2023.09.15. 11:25 Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Export Date: 11 October 2023 CODEN: VPAHA</pre> </div></div>